1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

EU Report Puts Generics And Biosimilars In The Frame

EU Also Needs More Teamwork On Drug Pricing & Access

 
• By Ian Schofield and Dave Wallace

EU member states are being urged by the European Commission to cooperate more closely on pricing and reimbursement, managed access deals and policies to promote generics and biosimilars.

PS1805_Teamwork_383615959_1200.jpg
The EU wants member states to work more cooperatively on medicines access • Source: Shutterstock

The European Commission is stepping up its efforts to improve access to medicines by calling on EU member states to cooperate more strategically in areas like pricing and reimbursement and health technology assessments, and to maximize the potential savings from generics and biosimilars.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

OGD’s Policy Office Cut To Have ‘Profound’ Impact On New Generic Approvals, Warns Former FDA Head Gottlieb

 
• By Urtė Fultinavičiūtė

The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.

More from Policy & Regulation